
Sign up to save your podcasts
Or
We’re back with our 4th episode in our collaborative series with BMJ Thorax. This week’s episode covers four articles related to bronchiectasis and covers a range of topics in this domain including novel therapeutics, registry data to understand risk, and health related quality of life.
Our mission at Pulm PEEPs is to disseminate and promote pulmonary and critical care education, and we highly value the importance of peer reviewed journals in this endeavor. Each month in BMJ Thorax, a journal club is published looking at high yield and impactful publications in pulmonary medicine. We will be putting out quarterly episodes in association with Thorax to discuss a journal club publication and synthesize four valuable papers.
Meet Our Guests
Chris Turnbull is an Associate Editor for Education at Thorax. He is an Honorary Researcher and Respiratory Medicine Consultant at Oxford University Hospitals. In addition to his role as Associate Editor for Education at BMJ Thorax, he is also a prominent researcher in sleep-related breathing disorders.
Dr. George Doumat completed his medical school at the American University of Beirut and now is an internal medicine resident at UT south western in his second year of training. Prior to starting residency he was a research fellow at MGH studying chronic lung disease.
Journal Club Papers
To submit a journal club article of your own to Thorax, you can contact Chris directly – [email protected]
To engage with Thorax, please use the social media channels (Twitter – @ThoraxBMJ; Facebook – Thorax.BMJ) and subscribe on your preferred platform, to get the latest episodes directly on your device each month.
Key Learning Points
1) ASPEN trial – brensocatib (DPP-1 inhibitor)
2) AIRLEAF (BI 1291583) – reversible cathepsin C inhibitor
3) U.S. Bronchiectasis & NTM Registry – 5-year outcomes
4) Bronch-UK cohort – anxiety & depression
Practical takeaways for clinic
Research/implementation gaps highlighted
Pro tip from the episode
When appraising trials, check the CONSORT diagram for generalizability and look for stratification methods in multinational RCTs; in phase 2 programs, expect model-based dose–response designs that trade breadth for power.
4.9
5353 ratings
We’re back with our 4th episode in our collaborative series with BMJ Thorax. This week’s episode covers four articles related to bronchiectasis and covers a range of topics in this domain including novel therapeutics, registry data to understand risk, and health related quality of life.
Our mission at Pulm PEEPs is to disseminate and promote pulmonary and critical care education, and we highly value the importance of peer reviewed journals in this endeavor. Each month in BMJ Thorax, a journal club is published looking at high yield and impactful publications in pulmonary medicine. We will be putting out quarterly episodes in association with Thorax to discuss a journal club publication and synthesize four valuable papers.
Meet Our Guests
Chris Turnbull is an Associate Editor for Education at Thorax. He is an Honorary Researcher and Respiratory Medicine Consultant at Oxford University Hospitals. In addition to his role as Associate Editor for Education at BMJ Thorax, he is also a prominent researcher in sleep-related breathing disorders.
Dr. George Doumat completed his medical school at the American University of Beirut and now is an internal medicine resident at UT south western in his second year of training. Prior to starting residency he was a research fellow at MGH studying chronic lung disease.
Journal Club Papers
To submit a journal club article of your own to Thorax, you can contact Chris directly – [email protected]
To engage with Thorax, please use the social media channels (Twitter – @ThoraxBMJ; Facebook – Thorax.BMJ) and subscribe on your preferred platform, to get the latest episodes directly on your device each month.
Key Learning Points
1) ASPEN trial – brensocatib (DPP-1 inhibitor)
2) AIRLEAF (BI 1291583) – reversible cathepsin C inhibitor
3) U.S. Bronchiectasis & NTM Registry – 5-year outcomes
4) Bronch-UK cohort – anxiety & depression
Practical takeaways for clinic
Research/implementation gaps highlighted
Pro tip from the episode
When appraising trials, check the CONSORT diagram for generalizability and look for stratification methods in multinational RCTs; in phase 2 programs, expect model-based dose–response designs that trade breadth for power.
1,866 Listeners
543 Listeners
266 Listeners
500 Listeners
3,340 Listeners
1,138 Listeners
192 Listeners
701 Listeners
515 Listeners
368 Listeners
249 Listeners
429 Listeners
253 Listeners
374 Listeners
235 Listeners